2 Billion people suffer from a disease of the Central Nervous System _a 100 Million of them in the US. Half the people satisfying the criteria for either dementia or depression have never received a diagnosis. Alzheimer’s alone is over a US$ 100B/year problem today. It will be a US$ 1 trillion / year in the next 15 years in the US alone. US$ 40 Billion per year is invested on drugs, 100 Million sentient vertebrates are sacrificed in the process, and only in 6% of cases do Pharmaceutical drugs get tested in expensive clinical trials, which a third of approved patients end up abandoning while the other two thirds produce unreliable assessments about their internal states. Of the drugs that are approved, many have devastating side effects.
When Philip Low was 9, his father was arrested for threatening someone with a firearm, an act later attributed to a sleep drug’s adverse reaction. With over a 100 Billion neurons in our brains, tremendous damage must take place, sometimes over a period of years, before abrupt changes in behavior are noticed. Dr. Low gives voice to the whispers of brains affected by disease or drug side effects. He has launched iBrain, a wireless non-invasive technology which has enabled to the World’s largest pharmaceutical companies, such as Roche and Novartis, to gather much more information about the brain and to conduct clinical trials remotely. He and his company, NeuroVigil, have been asked by Stephen Hawking to create a system to enable ALS sufferers to communicate with their minds and by NASA to track astronauts in Space.
Dr. Philip Low is our speaker at Saturday’s METal. He is Chairman, CSO and CEO of NeuroVigil, and the inventor, neurotechnologist and computational neuroscientist responsible for the SPEARS algorithm, the iBrain neural monitor, the Cambridge Declaration on Consciousness and the Curitiba Declaration. In his teens, he made discoveries at Harvard Med. In his twenties, he wrote a groundbreaking and the shortest PhD thesis in History (1 page, no joke), launched the 1st outpatient pharma clinical trial for the brain and had dual faculty and visiting appointments at Stanford and MIT. He was President of the 1st Intl. Congress on Alzheimer’s Disease and Advanced Neurotechnologies and of the historic Crick Memorial Conference which recognized consciousness in non-humans. He is an MIT Technology Review TR-35 Top Young Innovator along with the Founders of Google, Linux and Facebook and the inaugural winner of the Jacobs-Rady Pioneer Award. iBrain was listed by NY Times as one of “32 Innovations that Will Change Your Tomorrow” and won the CONNECT Most Innovative New Product Award. NeuroVigil won the DFJ Venture Challenge, the UCSD E. Challenge and was recognized by The Washington Post and Fast Company as one the Top 10 Most Innovative Companies in Health Care, alongside GE and the Cleveland Clinic. His work has been featured in many popular and technical publications, including the New York Times, TIME, the Economist, Forbes, PNAS and Scientist Magazine which has singled him out as "A Scientist to Watch". Dr. Low's mentors and colleagues have included Stephen Hawking and Nobel Laureates Francis Crick and Roger Guillemin. He is an advisor to the White House and the Israeli government. His backers and advisors include Irwin Jacobs and Elon Musk.
From October 04, 2014 10:30 am to 12:30 pm Save to calendar
(310) 305 - 4100